Lifecore Biomedical Warning Letter Spotlights Intergel Adverse Event Issues
This article was originally published in The Gray Sheet
Executive Summary
Lifecore Biomedical's efforts to bring its Intergel adhesion prevention solution back to the U.S. market may be slowed by a recent warning letter citing failure to report adverse events to FDA in a timely manner
You may also be interested in...
FDA Panel: Cardiac Surgery Adhesion Barrier Use Should Be Limited To Kids
SyntheMed's Repel-CV cardiac surgery adhesion barrier should be approved only for pediatric patients since pivotal trial data on newborns cannot be extrapolated to the adult population, FDA's Circulatory System Devices advisory panel recommended Sept. 19
FDA Panel: Cardiac Surgery Adhesion Barrier Use Should Be Limited To Kids
SyntheMed's Repel-CV cardiac surgery adhesion barrier should be approved only for pediatric patients since pivotal trial data on newborns cannot be extrapolated to the adult population, FDA's Circulatory System Devices advisory panel recommended Sept. 19
FDA Defends Its Line Of Communication As Lifecore Revamps MDR Procedures
Lifecore Biomedical had sufficient opportunity to obtain FDA guidance on medical device reporting (MDR) for theIntergel adhesion prevention solution, despite the firm's claims to the contrary, the agency maintains in a Dec. 1 letter